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detection of pre-symptomatic SARS-CoV-2 infection: 
a nested, case-control diagnostic accuracy study
Rishi K Gupta*, Joshua Rosenheim*, Lucy C Bell*, Aneesh Chandran, Jose A Guerra-Assuncao, Gabriele Pollara, Matthew Whelan, Jessica Artico, 
George Joy, Hibba Kurdi, Daniel M Altmann, Rosemary J Boyton, Mala K Maini, Aine McKnight, Jonathan Lambourne, Teresa Cutino-Moguel, 
Charlotte Manisty, Thomas A Treibel, James C Moon, Benjamin M Chain, Mahdad Noursadeghi, on behalf of the COVIDsortium Investigators†
Summary
Background We hypothesised that host-response biomarkers of viral infections might contribute to early identification 
of individuals infected with SARS-CoV-2, which is critical to breaking the chains of transmission. We aimed to 
evaluate the diagnostic accuracy of existing candidate whole-blood transcriptomic signatures for viral infection to 
predict positivity of nasopharyngeal SARS-CoV-2 PCR testing.
Methods We did a nested case-control diagnostic accuracy study among a prospective cohort of health-care workers 
(aged ≥18 years) at St Bartholomew’s Hospital (London, UK) undergoing weekly blood and nasopharyngeal swab 
sampling for whole-blood RNA sequencing and SARS-CoV-2 PCR testing, when fit to attend work. We identified 
candidate blood transcriptomic signatures for viral infection through a systematic literature search. We searched 
MEDLINE for articles published between database inception and Oct 12, 2020, using comprehensive MeSH and 
keyword terms for “viral infection”, “transcriptome”, “biomarker”, and “blood”. We reconstructed signature scores in 
blood RNA sequencing data and evaluated their diagnostic accuracy for contemporaneous SARS-CoV-2 infection, 
compared with the gold standard of SARS-CoV-2 PCR testing, by quantifying the area under the receiver operating 
characteristic curve (AUROC), sensitivities, and specificities at a standardised Z score of at least 2 based on the 
distribution of signature scores in test-negative controls. We used pairwise DeLong tests compared with the most 
discriminating signature to identify the subset of best performing biomarkers. We evaluated associations between 
signature expression, viral load (using PCR cycle thresholds), and symptom status visually and using Spearman rank 
correlation. The primary outcome was the AUROC for discriminating between samples from participants who tested 
negative throughout the study (test-negative controls) and samples from participants with PCR-confirmed SARS-CoV-2 
infection (test-positive participants) during their first week of PCR positivity.
Findings We identified 20 candidate blood transcriptomic signatures of viral infection from 18 studies and evaluated 
their accuracy among 169 blood RNA samples from 96 participants over 24 weeks. Participants were recruited between 
March 23 and March 31, 2020. 114 samples were from 41 participants with SARS-CoV-2 infection, and 55 samples were 
from 55 test-negative controls. The median age of participants was 36 years (IQR 27–47) and 69 (72%) of 96 were 
women. Signatures had little overlap of component genes, but were mostly correlated as components of type I 
interferon responses. A single blood transcript for IFI27 provided the highest accuracy for discriminating between 
test-negative controls and test-positive individuals at the time of their first positive SARS-CoV-2 PCR result, with 
AUROC of 0·95 (95% CI 0·91–0·99), sensitivity 0·84 (0·70–0·93), and specificity 0·95 (0·85–0·98) at a predefined 
threshold (Z score >2). The transcript performed equally well in individuals with and without symptoms. Three other 
candidate signatures (including two to 48 transcripts) had statistically equivalent discrimination to IFI27 (AUROCs 
0·91–0·95).
Interpretation Our findings support further urgent evaluation and development of blood IFI27 transcripts as a 
biomarker for early phase SARS-CoV-2 infection for screening individuals at high risk of infection, such as contacts 
of index cases, to facilitate early case isolation and early use of antiviral treatments as they emerge.
Funding Barts Charity, Wellcome Trust, and National Institute of Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Rapid and accurate testing is central to effective public 
health responses to COVID-19. Infectivity, measured by 
SARS-CoV-2 titres in the upper respiratory tract, peaks 
during the first week of symptoms.1 Early case detection 
and subsequent rapid isolation of index cases, alongside 
contact tracing and quarantine, are key interventions to 
interrupt onward transmission. Because some individuals 
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with SARS-CoV-2 shed virus while asymptomatic or pauci-
symptomatic,2,3 there is also global interest in screening 
tests for at-risk individuals who do not fulfil case definition 
criteria and in mass testing for early case detection among 
the general population regardless of symptoms.4
Effective screening tests must be accurate and reliable.5 
Current tools, such as lateral flow assays for SARS-CoV-2 
antigens, have inadequate sensitivity to effectively rule 
out active infection and might have low value for contact 
and general population screening.6 RT-PCR tests, which 
identify viral RNA, are the current gold standard for 
diagnosis of SARS-CoV-2 infection, but pose various 
challenges including test speed and the requirement of a 
skilled laboratory operator.7 Loop-mediated isothermal 
amplification (referred to as LAMP) assays have quicker 
test speeds than RT-PCR timings, but with an asso-
ciated reduction in sensitivity.8 All detection tests 
currently available for SARS-CoV-2 rely on swabbing of 
nasopharyngeal or oropharyngeal mucosa, or both, the 
effectiveness of which is operator-dependent and prone to 
sampling variability. Although positive SARS-CoV-2 test 
results are useful in clinical management and infection 
control settings, negative results—in the context of high 
pre-test probability of a positive finding—mean that the 
current tests cannot be used to rule out infection 
effectively.9
There is a clear need to expand the portfolio of tests 
available for the identification of SARS-CoV-2 infection, 
for both screening and diagnostic purposes. Measure-
ment of the host response, as opposed to viral targets, is 
one potential diagnostic strategy. Numerous studies have 
demonstrated whole-blood transcriptional perturbation 
during other acute viral infections, such as influenza, 
rhinovirus, and respiratory syncitial virus.10–13 A range of 
blood trans criptomic signatures have, therefore, been 
proposed as candidate diagnostic biomarkers for various 
purposes, including discrimination of viral from bacterial 
infection or no infection,10–21 diagnosis of pre-symptomatic 
viral infection in known contacts,22 diagnosis of specific 
viral infections,23,24 or prediction of severity.25 These 
signatures have not yet been evaluated for early diagnosis 
of pre-symptomatic or mild SARS-CoV-2 infection. We 
aimed to systematically evaluate the potential for existing 
candidate whole-blood transcriptomic signatures of viral 
infection to predict nasopharyngeal SARS-CoV-2 PCR test 
positivity in health-care workers undergoing weekly 
testing with paired blood RNA sampling.
Methods
Study design and participants
This prospective diagnostic accuracy study, with a case-
control design, was nested within our COVIDsortium 
observational cohort study in health-care workers 
(NCT04318314). Participant screening, study design, 
sample collection, and sample processing have been 
described previously.26–28 Briefly, health-care workers 
(aged ≥18 years) were recruited at St Bartholomew’s 
Hospital, London, UK in the first week of lockdown in 
the UK (between March 23 and March 31, 2020). 
Participants were assessed weekly using a questionnaire 
and paired serial sampling of blood (for RNA sequencing 
and SARS-CoV-2 serology) and nasopharyngeal swabs 
(for viral PCR), for up to 16 weeks when they were fit 
enough to attend work (according to Barts Health NHS 
Trust policy) at each visit, with further follow-up samples 
collected at week 24. The questionnaire included 
questions about symptom burden; symptoms were 
classified as case defining (fever, new continuous dry 
Research in context
Evidence before this study
We searched MEDLINE for studies published between database 
inception and Oct 12, 2020, using comprehensive search terms 
for “biomarker”, “viral infection”, “blood”, and “transcriptome”. 
We did not restrict by language or study type. Full details of our 
search strategy are in appendix 1 (p 5). Our search returned 
1150 studies, 61 of which were relevant to this topic. Early case 
detection and isolation are key interventions to interrupt 
transmission of SARS-CoV-2 infection. A range of blood 
transcriptomic biomarkers have been proposed for the 
detection of viral infections. However, the diagnostic accuracy 
of these candidate signatures has not been previously 
evaluated for early SARS-CoV-2 infection.
Added value of this study
In this prospective diagnostic accuracy study within a cohort of 
health-care workers with paired serial sampling of blood (for RNA 
sequencing and SARS-CoV-2 serology) and nasopharyngeal 
swabs (for viral PCR), we identified 20 previously proposed blood 
transcriptomic signatures for viral infection through our 
systematic literature search, and calculated signature scores for 
each sample according to original descriptions. Four signatures 
reflecting type I interferon signalling (including a single transcript 
IFI27) discriminated between test-negative controls and 
contemporaneous SARS-CoV-2 PCR positivity, with statistically 
equivalent performance. Using a pre-specified diagnostic 
threshold, IFI27 achieved sensitivity of 84% (95% CI 70–93) and 
specificity of 95% (85–98) for contemporaneous PCR positivity, 
with sensitivity at 40% (17–69) 1 week before first positive 
PCR test.
Implications of all the available evidence
Blood transcriptomic biomarkers for viral infection, including 
IFI27, reflect underlying type I interferon responses and detect 
early SARS-CoV-2 infection with high accuracy. If these 
biomarkers are included in scalable point-of-care tests for 
SARS-CoV-2, they could facilitate early case detection and 
contact investigation.
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cough, or a new loss of taste or smell [anosmia]), non-
case defining (specific symptoms other than case-
defining symptoms, or unspecified symptoms), or 
asymptomatic (no symptoms reported).
Participants who were not available for a particular visit 
(eg, due to shift pattern, annual leave redeployment, self-
isolation, or illness) resumed follow-up on their return to 
work.
We used the Roche cobas 8800 diagnostic test platform 
(Burgess Hill, UK) as the standard reference for PCR 
confirmation of SARS-CoV-2 infection, with a cycle 
threshold of 40. Participants with available blood RNA 
samples who had PCR-confirmed SARS-CoV-2 infection 
at any timepoint during the study were included in 
the test-positive group (ie, cases) and their blood RNA 
samples were sequenced. A subset of consecutively 
recruited participants without evidence of SARS-CoV-2 
infection on nasopharyngeal swabs and who remained 
seronegative by both Euroimmun anti-S1 spike protein 
and Roche anti-nucleocapsid protein throughout follow-
up were included in the test-negative control group; only 
their baseline blood RNA samples were sequenced.
The study was approved by the South Central–Oxford A 
Research Ethics Committee (reference 20/SC/0149), and 
the study was done in accordance with the principles of 
the Declaration of Helsinki and Good Clinical Practice. 
All participants provided written informed consent.
Systematic search for candidate transcriptional 
signatures
We did a systematic literature search of peer-reviewed 
publications to identify concise blood transcriptional 
signatures discovered or applied with a primary objective 
of diagnosis or assessment of severity of viral infection 
from human whole-blood or peripheral blood mono-
nuclear cell samples. We searched MEDLINE for 
articles published between database inception and 
Oct 12, 2020, using comprehensive MeSH and keyword 
terms for “viral infection”, “transcriptome”, “biomarker”, 
and “blood”. Our search had no language restrictions. Our 
full search strategy is in appendix 1 (p 5). We identified 
additional studies in reference lists and from expert 
consultation. Titles and abstracts were initially screened 
by two independent reviewers (RKG and LCB); full-text 
reviews were done for shortlisted articles to determine 
eligibility and conflicts were resolved through discussion 
and arbitration by a third reviewer (MN) where required. 
We focused on concise signatures that might be more 
amenable to translation to diagnostic tests; we defined 
concise signatures as any signature discovered using a 
defined approach to feature selection to reduce the 
number of constituent genes, as previously described.29 
We required that gene names that comprised the signature 
were publicly available, along with the corresponding 
signature equation or model coefficients, and that the 
signature was validated in at least one independent test or 
validation set to prioritise signatures discovered from 
higher quality studies. Where multiple signatures were 
discovered for the same intended purpose and from the 
same discovery cohort, we included the signature with 
highest discrimination (as defined by the area under the 
receiver operating characteristic curve [AUROC]) in the 
validation data, or the signature with the fewest number 
of genes when accuracy was equivalent.
For each signature that met our eligibility criteria, 
we extracted constituent genes, modelling approaches, 
and coefficients to enable independent reconstruction of 
signature scores. Extraction was done by one reviewer 
(RKG) and was verified by a second reviewer (LCB).
We refer to RNA signatures by combining the first 
author’s name of the corresponding publication as a 
prefix, with the number of constituent genes as a suffix; 
except for single-gene signatures, which are referred to 
by the gene name.
Blood RNA sequencing
For the positive-test group, we included all available RNA 
samples within 3 weeks of first positive SARS-CoV-2 PCR 
test, and convalescent samples at week 24 of follow-up for 
a subset of participants with available samples. For the 
control group, we included baseline samples only. 
Genome-wide mRNA sequencing was done as previously 
Figure 1: Study profile
45 individuals with SARS-CoV-2-
       positive PCR results 
114 blood RNA samples from 
41 individuals with 
SARS-CoV-2-positive PCR 
results during the study period 
(test-positive group)
4 excluded 
    4 data not available
400 health-care workers recruited 
to cohort for weekly sampling
 
300 excluded 
         300 data not required,
                   test-negative target reached
55 baseline blood RNA samples from 
55 uninfected individuals 
(test-negative controls) with 
>4 weeks of continuous follow-up
13 samples from 
12 individuals with 
samples collected 
≤3 weeks before 
PCR-positivity
38 samples from 
38 individuals at 
time of
PCR-positivity
47 samples from 
25 individuals
       collected 
3 weeks after 
PCR-positivity
16 samples from 
16 individuals 
collected 24 weeks 
after PCR-positivity
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described30 using the Kappa Hyperprep kit (Roche; 
Burgess Hill, UK) to generate complementary DNA 
libraries sequenced on the Illumina Nextseq platform 
using the Nextseq 500/550 High Output 75 cycle kit 
(Illumina; Cambridge, UK) according to manufacturers’ 
instructions, giving a median of 26 million (range 
19·8–32·4) 41-base pair paired-end reads per sample. We 
mapped RNAseq data to the reference transcriptome 
(Ensembl Human GRCh38 release 100) using Kallisto 
(version 0.46.1).31 The transcript-level output counts and 
Model* Discovery populations Discovery 
settings
Discovery approach Validation populations Intended 
application
AndresTerre1123 Geometric mean of all 
genes (influenza 
meta-signature)
Five cohorts of children and adults 
with influenza; adults challenged 
with influenza; and adults with 
bacterial pneumonia
UK, USA, and 
Australia
Differential expression followed 
by leave-one-cohort-out 
strategy and filtering for 
heterogeneity of effect size, 
using genome-wide data
Eight cohorts of children or 
adults with influenza or 
bacterial infection; adults 
challenged with influenza; 
and adults vaccinated against 
influenza
Influenza vs bacterial 
or other viral 
infection






Four cohorts of children with 
influenza-like illness
USA Meta-analysis and leave-one-
out strategy to identify 
common genes using genome-
wide data
Two cohorts of children or 
adults with influenza
Influenza infection vs 
healthy
Herberg210 Disease risk score† Children with viral or bacterial 
infection
UK, USA, and 
Spain
Elastic net followed by forward 
selection–partial least squares, 
using significantly differentially 
expressed transcripts
Children with bacterial or viral 
infection, inflammatory 
disease, or indeterminate 
diagnosis
Viral vs bacterial 
infection in febrile 
children
IFI44L14 NA Children with viral or bacterial 
infection10
UK, USA, and 
Spain
Elastic net followed by forward 
selection–partial least squares, 
using significantly differentially 
expressed transcripts
Children with bacterial or viral 
infection
Viral vs bacterial 




NA Three cohorts of adults challenged 
with rhinovirus, influenza, or RSV35
UK and USA Sparse latent factor regression 
analysis on genome-wide data35 
followed by regularised logistic 
regression on the resulting 
30-gene signature
Close contacts of students 
with acute upper respiratory 
viral infections
Pre-symptomatic 
viral infection vs 
healthy
Lopez715 Sum of weighted gene 
expression values 
(bacterial vs viral 
classifier)
Children and adults with viral, 
bacterial, or non-infectious acute 
respiratory illness19
USA Support vector machine analysis 
using genome-wide data
Children with acute viral or 
bacterial infections36
Viral vs bacterial 
respiratory infection
Lydon1511 Logistic regression (viral 
classifier)§
Adolescents and adults with viral, 
bacterial, or non-infectious acute 
respiratory illness
USA LASSO regression analysis using 
87 selected target genes from 
previously derived signatures19,21
Patients with viral or bacterial 
co-infection or suspected 
bacterial infection
Viral vs bacterial 
respiratory infection
MX137 NA NA NA Preselected due to biological 
plausibility
Adults challenged with the 
live yellow fever virus vaccine
Viral infection vs 
healthy
OLFM425 NA Children with RSV infection The Netherlands Differential expression and 
prediction analysis of 
microarrays classifier training 
using genome-wide data
A second cohort of children 
with RSV infection
Severity of RSV 
infection in children
Pennisi220 Disease risk score† Children with viral or bacterial 
infection10
UK, USA, and 
Spain
Elastic net followed by forward 
selection–partial least squares, 
using significantly differentially 
expressed transcripts,10 then 
selection of an adequately 
expressed transcript for use in 
RT-LAMP
Children with bacterial or viral 
infection
Viral vs bacterial 
infection in children
Sampson1013 Disease risk score 
(combined SeptiCyte 
score)
Eight cohorts of neonates, 
children, and adults with bacterial 
infections
UK, USA, Estonia, 
and Australia
Regression analysis of transcript 
pairs using the 6000 most 
highly expressed genes from 
each dataset
Unselected consecutive 
patients presenting to the 
emergency department with 
febrile illness
Viral vs bacterial in 
febrile patients
Sampson416 Disease risk score 
(Septicyte VIRUS)
Ten cohorts of children and adults 
with viral infections; two cohorts 
of adults challenged with 
influenza; and two cohorts of 
macaques challenged with Lassa 





Regression analysis of transcript 
pairs using the 6000 most 
highly expressed genes from 
each dataset
Seven human cohorts and 
six non-human mammal 
cohorts infected or challenged 
with viruses across all seven of 
the Baltimore virus 
classification groups
Viral vs non-viral 
conditions
(Table 1 continues on next page)
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transcripts per million values were summed on gene level 
and annotated with Ensembl gene ID, gene name, and 
gene biotype using the tximport (version 1.20.0) and 
biomaRt (version 2.48.0) Bioconductor packages in R.32,33
Outcomes
The primary outcome was the AUROC for discriminating 
between control samples and samples from participants 
with PCR-confirmed SARS-CoV-2 infection during their 
first week of PCR test positivity. The secondary outcome 
was the AUROC for discriminating between control 
samples and samples from participants with PCR-
confirmed SARS-CoV-2 infections in the week before 
first positive PCR test.
Statistical analysis
The statistical power in our primary analysis is provided 
for a range of AUROCs 0·5–1·0 (appendix 1, p 3). Our 
sample size provided more than 90% power to discriminate 
between test-positive cases and test-negative controls with 
an AUROC of at least 0·7. For each eligible signature, we 
reconstructed signature scores as per the original authors’ 
descriptions. For logistic and probit regression models, we 
calculated scores on the linear predictor scale by summing 
the expression of each constituent gene multiplied by its 
coefficient. Scores for each signature were standardised to 
Z scores using the mean and SD among the control group. 
We multiplied scores that were designed to decrease 
in viral infection by −1 to ensure that higher scores were 
associated with higher risk of viral infection across all 
candidate signatures.
We calculated AUROCs and corresponding sensitivities 
and specificities with 95% CIs for each signature for the 
primary and secondary outcomes using prespecified 
cutoffs based on two SDs above the mean value of the 
controls (referred to as Z2) as previously described.29 To 
Model* Discovery populations Discovery 
settings
Discovery approach Validation populations Intended 
application
(Continued from previous page)




multiplied by ratio of 
counts of positive to 
negative genes (Sepsis 
metascore)
Nine cohorts of patients with 
sepsis or trauma
USA, Australia, 




Greedy forward search of 
82 differentially expressed 
genes identified by multicohort 
analysis
12 cohorts of adults with viral 
or bacterial sepsis, or trauma
Viral or bacterial 
sepsis vs sterile 
inflammation




multiplied by ratio of 
counts of positive to 
negative genes (bacterial 
or viral metascore)
Eight cohorts of children and 
adults with viral and bacterial 
infections
USA, Australia, UK Greedy forward search of 
72 differentially expressed genes 
identified by multicohort 
analysis
24 cohorts of children and 
adults with viral or bacterial 
infections, or healthy controls




Median expression of 
six interferon-stimulated 
genes (interferon score38)
NA NA Differential expression using 
15 preselected interferon-
stimulated genes
Febrile children with bacterial 
or viral infection
Viral vs bacterial 
infection in febrile 
children
Tsalik3319 Logistic regression (viral 
ARI classifier)§
Children and adults with viral, 
bacterial, or non-infectious acute 
respiratory illness, and healthy 
controls
USA LASSO regression analysis using 
the 40% of microarray probes 
with the largest variance after 
batch correction
Five cohorts of children or 
adults with viral, bacterial, 
or non-infectious respiratory 
illness, or viral or bacterial 
co-infection





Yu3: mean expression 
(non-RSV infections vs 
controls); IFI27: NA
Children with acute respiratory 
illness and a positive result for a 
viral infection on a nasopharyngeal 
swab
USA Modified supervised principal 
component analysis using all 
expressed transcripts
Children with RSV or 
rhinovirus infection
Viral vs healthy in 
children
Zaas4821 Probit regression (viral 
classifier)§
Two cohorts of adults challenged 
with influenza A H3N2 or H1N1
USA Elastic net using 48 selected 
genes comprised of: 29 derived 
as a signature in a previous 
study,35 seven shown to be 
downregulated in analysis of 
influenza challenge time course 
data,40 and 12 control genes
Adults presenting to the 
emergency department with 
fever and healthy controls
Viral vs bacterial 
acute respiratory 
illness
Log2-transformed transcripts per million data were used to calculate all signatures. NA=not applicable. RSV=respiratory syncytial virus. LASSO=least absolute shrinkage selector operator. RT-LAMP=reverse 
transcription loop-mediated isothermal amplification. *Where applicable, the name of the signature from the original publication is indicated in brackets. †Defined as the sum of downregulated genes 
subtracted from the sum of upregulated genes. ‡Study by McClain and colleagues22 sought to validate a 36-transcript signature for the detection of respiratory viral infections. Model coefficients for the 
36-transcript model are not provided; therefore, we included in this analysis the two best performing single transcripts from the study, since they had similar performance to the full model in the original 
publication. §Logistic and probit regression models were calculated on the linear predictor scale using model coefficients from original publications.
Table 1: Characteristics of whole-blood RNA signatures for viral infection included in analysis
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identify the subset of best performing signatures, we used 
pairwise DeLong tests for the signature with the highest 
AUROC for the primary outcome (or most parsimonious 
in the event of equal performance), with adjustment for 
mul tiple testing using a Benjamini-Hochberg correction.34 
Signatures were considered to have statistically inferior 
accuracy to the best performing signature if the adjusted 
value was p<0·05. We evaluated associations between the 
best performing signatures and SARS-CoV-2 PCR cycle 
thresholds among people with contemporaneous PCR test 
positivity visually using scatterplots and Spearman rank 
correlation (reported as r).
We used Ingenuity Pathway Analysis (Qiagen; Venlo, 
Netherlands) for upstream analysis of transcriptional 
regulation of the constituent genes in the candidate 
signatures. Findings were visualised as network diagrams 
in Gephi (version 0.9.2), depicting all statistically over-
represented molecules that were predicted to be upstream 
of at least two target genes, as previously described.29 We 
evaluated pairwise Spearman rank and Jaccard indices 
between each candidate signature to quantify correlations 
and proportions of intersecting genes between signatures.
We did sensitivity analyses to assess the effect of various 
factors on our findings. First, we recalculated discrimi-
nation (AUROC) for the pri mary outcome, excluding 
participants with positive SARS-CoV-2 nasopharyngeal 
swabs who reported contemporaneous case-defining 
symptoms at the time of sampling to evaluate diagnostic 
accuracy for people without case-defining symptoms. 
Second, we assessed the discrimination of the best 
performing signatures when using peak signatures scores 
for each participant during follow-up. Finally, we used a 
multi variable linear regression model to evaluate whether 
age, sex, or presence of concurrent case-defining 
symptoms were associated with expression of the best 
performing signature, after adjustment for the SARS-CoV-2 
PCR cycle threshold.
We used R (version 3.6.3) for all statistical analyses.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Between March 23 and March 31, 2020, we recruited 
health-care workers for this analysis. We included 
169 blood RNA samples from 96 participants in a nested 
case-control study (figure 1) derived from an observational 
health-care worker cohort.26–28 Of these, 114 samples 
(including 16 convalescent samples collected 24 weeks 
after infection) were from 41 participants with 
SARS-CoV-2 infection during the study period, and 
55 samples were from 55 test-negative controls.
The median age of participants was 36 years (IQR 27–47) 
and 69 (72%) of 96 were female; White (66 participants 
[69%]) was the most common ethnicity, followed by 
Asian (18 [19%]) and Black (six [6%]). Full baseline 
characteristics and the number of included blood RNA 
samples per participant are listed in appendix 1 (p 6). 
32 (78%) of 41 test-positive participants denied having 
any disease defining symptoms at the time of their 
SARS-CoV-2-positive PCR test, whilst nine (22%) of 
41 described having one or more of cough, fever, or 
anosmia. A further 22 participants developed symptoms 
during subsequent follow-up. All symptomatic parti-
cipants had mild disease. None of the control participants 
had alternative diagnoses.
Our systematic literature search found 1150 titles and 
abstracts; 61 studies were shortlisted for full-text review. 18 
studies, describing 20 distinct transcriptional signatures 
for viral infection, met the eligibility criteria for inclusion 
Figure 2: Correlation and Jaccard indices for all eligible RNA signatures for viral infection
(A) Jaccard index intersect of constituent genes for all pairs of signatures clustered by Euclidean distance, 
indicating the proportion of the gene list that overlap in each pairwise comparison of signatures. The order of 
row labels for individual signatures is mirrored in the columns of the heatmap. (B) Spearman rank correlation 
coefficients for all pairs of signatures clustered by 1 – Spearman rank distance. The order of row labels for individual 
signatures is mirrored in the columns of the heatmap. (C) Relationship between pairwise Jaccard indices and 
Spearman rank correlation coefficients. (D) Network plot of significantly enriched predicted upstream regulators 
by cytokine, transmembrane receptors, kinase, and transcription factors of all constituent genes in any signature. 
The size of upstream regulator nodes is proportional to statistical enrichment. Node labels are shown for the ten 
most statistically enriched upstream regulators (false discovery rate <5 × 10⁻¹⁷). Full details of our upstream 
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in the final analysis (table 1; appendix 1 p 2). Signatures 
comprised between two and 48 component genes and 
were discovered in various populations, including children 
and adults with acute viral infections, adults experimentally 
challenged with viruses (such as influenza, respiratory 
syncytial virus [RSV], and rhinovirus). 12 (60%) of 20 
signatures were discovered with the objective of 
discriminating viral infection from bacterial or other 
inflammatory presentations.10–21 Three signatures aimed to 
discriminate between healthy individuals and those with 
viral infection37,39 and two were discovered with a specific 
objective of diagnosing influenza infection.23,24 One 
signature aimed to predict the severity of RSV infection in 
children.25 One study evaluated a pre-existing signature 
with the aim of identifying pre-symptomatic viral infection 
in individuals who were close contacts of index cases with 
acute viral respiratory tract infections.22
In most instances there was little overlap between the 
constituent genes in each signature, but most signatures 
showed moderate to strong correlation, which was only 
partly explained by overlapping constituent genes 
(figure 2A–C). Bioinfor matic analysis of the integrated 
list of constituent genes to identify upstream regulators 
using Ingenuity Pathway Analysis was consistent with 
type I interferon (IFN) regulation of these genes, which 
would explain the strong correlation between signatures 
despite limited overlap of their constituents (figure 2D; 
appendix 2).
Among all the signatures, the transcript for IFN alpha 
inducible protein 27 (IFI27) alone provided the best dis-
crimination of contemporaneous SARS-CoV-2 infection 
by nasopharyngeal PCR, compared with test-negative 
controls, achieving an AUROC of 0·95 (95% CI 
0·91–0·99; table 2). Using a prespecified Z2 cutoff 
based on two SDs above the mean of the test-negative 
control samples, IFI27 had a sensitivity of 0·84 (95% CI 
0·70–0·93) and specificity of 0·95 (0·85–0·98). Three 
other candidate signatures (Sweeney7, Zaas48, 
and Pennisi2) had statistically equivalent accuracy to 
IFI27 using paired DeLong tests (AUROCs 0·91–0·95; 
table 2). Constituent genes for these four best 
performing signatures are shown in appendix 1 (p 3), of 
which only Pennisi2 did not include IFI27. Longitudinal 
expression of the four best performing signatures is 
shown in figure 3A. As a group, these peaked at the 
week of first positive SARS-CoV-2 PCR test and 
normalised at the timepoint of convalescent sampling 
(week 24). Scores for each of the four best performing 
signatures were inversely correlated with SARS-CoV-2 
RT-PCR cycle thresholds, but were visually independent 
of current case-defining symptoms, suggesting that 
higher viral loads were associated with higher signature 
scores (figure 3B; r −0·61 to −0·69).
For the four best performing signatures, measurements 
in the week preceding the first SARS-CoV-2-positive PCR 
test were higher than those of controls and convalescent 
samples (figure 3A). AUROCs for discrimination between 
control samples and samples taken in the week before 
first SARS-CoV-2-positive PCR test showed significant 
discrimination for 12 of the 20 signatures assessed, but 
were lower than those for contemporaneous virus PCR 
positivity (appendix 1 p 7). Notably, IFI27 predicted 
SARS-CoV-2 infection 1 week before a positive virus PCR 
test with an AUROC of 0·79 (95% CI 0·60–0·98). At Z2 
cutoff, sensitivity was 0·40 (0·17–0·69) and specificity 
was 0·95 (0·85–0·98).
Exclusion of participants with contemporaneous case-
defining symptoms at the time of SARS-CoV-2 infection 
(nine participants) did not affect the primary outcome 
(appendix 1 p 8). Evaluation of peak signature scores 
during follow-up for the four best performing signatures 
showed similar discrimination between the test-positive 
group and the test-negative control group for the primary 
endpoint (appendix 1 p 4). In a multi variable linear 
regression model, PCR cycle threshold was strongly 
inversely associated with the outcome of IFI27 expression 
at the time of contemporaneous SARS-CoV-2-positive PCR 
test (appendix 1 p 9). However, there were no asso ciations 
between age, sex, or current symptoms and IFI27 scores.
Discussion
To our knowledge, our diagnostic accuracy study is the 
first evaluation of host transcriptomic signatures for the 
AUROC Sensitivity Specificity Adjusted p value
IFI27 0·95 (0·91–0·99) 0·84 (0·70–0·93) 0·95 (0·85–0·98) ··
Sweeney7 0·95 (0·91–0·99) 0·82 (0·67–0·91) 0·95 (0·85–0·98) 0·85
Zaas48 0·93 (0·88–0·98) 0·61 (0·45–0·74) 0·95 (0·85–0·98) 0·088
Pennisi2 0·91 (0·86–0·96) 0·58 (0·42–0·72) 0·95 (0·85–0·98) 0·088
IFI44L 0·90 (0·84–0·96) 0·55 (0·40–0·70) 0·95 (0·85–0·98) 0·039
AndresTerre11 0·89 (0·83–0·95) 0·55 (0·40–0·70) 0·95 (0·85–0·98) 0·021
Henrickson16 0·89 (0·82–0·96) 0·55 (0·40–0·70) 0·93 (0·83–0·97) 0·0093
TrouilletAssant6 0·87 (0·80–0·94) 0·53 (0·37–0·68) 0·93 (0·83–0·97) 0·008
Lydon15 0·86 (0·79–0·94) 0·58 (0·42–0·72) 0·95 (0·85–0·98) 0·0046
Herberg2 0·84 (0·76–0·92) 0·5 (0·35–0·65) 0·93 (0·83–0·97) 0·0034
Sampson4 0·84 (0·76–0·92) 0·5 (0·35–0·65) 0·93 (0·83–0·97) 0·0027
Sampson10 0·83 (0·74–0·92) 0·5 (0·35–0·65) 0·95 (0·85–0·98) 0·0021
RSAD2 0·83 (0·74–0·91) 0·47 (0·32–0·63) 0·93 (0·83–0·97) 0·0021
MX1 0·82 (0·74–0·91) 0·45 (0·30–0·60) 0·95 (0·85–0·98) 0·0017
Tsalik33 0·79 (0·70–0·89) 0·39 (0·26–0·55) 0·98 (0·9–1·0) 0·0011
Lopez7 0·79 (0·69–0·88) 0·37 (0·23–0·53) 0·98 (0·9–1·0) 0·00080
IFIT3 0·75 (0·64–0·86) 0·45 (0·30–0·60) 0·93 (0·83–0·97) 0·00027
OLFM4 0·62 (0·51–0·74) 0·03 (0·0–0·13) 0·98 (0·9–1·0) <0·0001
Sweeney11 0·60 (0·48–0·73) 0·16 (0·07–0·30) 0·96 (0·88–0·99) <0·0001
Yu3 0·59 (0·47–0·71) 0·05 (0·01–0·17) 1 (0·93–1·0) <0·0001
Data are point estimates (95% CIs). Includes 38 contemporaneous SARS-CoV-2-positive samples and 55 SARS-CoV-2-
negative samples. Discrimination is shown as AUROC. Sensitivity and specificity are shown using predefined thresholds 
of 2 SDs above the mean of the uninfected control population (Z2). p values show pairwise comparisons to best 
performing signature with Benjamini-Hochberg adjustment (false discovery rate 0·05). Equivalent data for 
discrimination between test-negative controls and participants with SARS-CoV-2 infection 1 week before positive PCR 
test are in appendix 1 (p 7). AUROC=area under the receiver operating characteristic curve.
Table 2: Validation metrics of whole-blood RNA signatures for discrimination of participants with 
PCR-confirmed SARS-CoV-2 infection at first week of PCR positivity
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detection of pre-symptomatic SARS-CoV-2 infection. 
By using a longitudinal blood transcriptomic dataset 
prospectively collected from health-care workers in 
London, UK, during the first wave of the COVID-19 
pandemic, we systematically compared the diagnostic 
accuracy of 20 candidate transcriptional signatures 
originally discovered in a wide range of viral infection 
cohorts. We found that four candidate signatures—IFI27, 
Sweeney7, Zaas48, and Pennisi2—had high accuracy for 
discriminating between test-negative controls and test-
positive participants at the time of their first SARS-CoV-
2-positive PCR test (AUROCs 0·91–0·95). Three of the 
four signatures contained the IFN-stimulated gene 
IFI27, which was the top-performing biomarker; IFI27 
was originally discovered in a paediatric cohort39 to 
discriminate between healthy controls and those with 
RSV infection. Notably, IFI27 has also been shown to 
discriminate well between influenza and bacterial 
infections when measured using RT-PCR among people 
with suspected respiratory tract infection, further 
supporting its potential clinical utility for the detection of 
respiratory viruses.41
The candidate signatures we evaluated are collectively 
associated with type I IFN responses, which are a 
canonical feature of antiviral host defences. The impor-
tance of this response in SARS-CoV-2 infection is 
highlighted by the association of severe COVID-19 with 
loss-of-function genetic variation in various components 
of type I IFN pathways and with anti-type I IFN 
antibodies.42–44 IFI27 is best characterised for its functional 
role in type I IFN-mediated apoptosis as a component of 
antitumour effects of IFNs.45 Differential regulation of 
IFN-inducible genes might explain why expression of 
IFI27 transcripts outperforms other type I IFN signatures 
and merits further investigation to evaluate the 
significance of its role in the antiviral response.
A key feature of our study is that all participants self-
declared as fit to work when attending study visits, 
including at the time of their first positive SARS-CoV-2 
PCR test, when most participants were asymptomatic. 
We also found detectable expression of the signatures in 
blood transcriptomes collected at the study visit 1 week 
before the first SARS-CoV-2-positive PCR test among 
a subset of participants. Our data, therefore, show 
that measurable type I IFN-stimulated responses to 
Figure 3: Four best performing RNA signatures for discriminating between 
controls and test-positive participants at the time of SARS-CoV-2-positive 
PCR test
(A) Z scores for each RNA signature in the test-negative control group and in the 
test-positive control group, stratified by time relative to first SARS-CoV-2-
positive PCR test. Convalescent samples were collected at study week 24. AUROC 
(95% CI) are for discriminating between test-negative controls and test-positive 
participants at the time of first SARS-CoV-2-positive PCR test (0 weeks). 
(B) Z scores versus contemporaneous PCR cycle threshold for SARS-CoV-2 open 
reading frame 1, with Spearman rank correlation coefficients. AUROC=area 
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SARS-CoV-2 precede the onset of symptoms and, in some 
individuals, might predate detectable viral RNA on 
RT-PCR testing. These findings are consistent with 
previous data showing that transcriptional perturbation 
preceded symptom onset and detectable viral shedding 
among a subset of contacts of people with respiratory 
viral infections.22 The point estimate for sensitivity to 
detect SARS-CoV-2 infection before PCR detection was 
modest, but larger studies are required to obtain precise 
performance metrics. We propose that novel diagnostic 
tests that detect transcripts (or associated protein targets) 
from the four top-performing candidate signatures we 
identified could be valuable tools in the rapid detection 
and isolation of individuals in the very early stages of 
preclinical infection with SARS-CoV-2. Notably, these 
signatures also correlated with viral load independently of 
symptoms, indicating that they have strong potential to 
identify the most infectious individuals, which is critical 
to breaking the chains of transmission for SARS-CoV-2.
A key strength of our study was the weekly longitudinal 
follow-up of study participants, which enabled detailed 
characterisation of the study cohort, including con-
temporaneous capture of blood RNA samples at the 
point of SARS-CoV-2 PCR positivity in pre-symptomatic 
and asymptomatic infection. We also did a comprehensive 
systematic literature search to identify candidate blood 
transcriptional signatures for viral infection. This 
search enabled direct head-to-head assessments of the 
signatures’ diagnostic accuracy for SARS-CoV-2 infection 
and will provide a framework for future systematic 
evaluations of blood transcriptional biomarkers for viral 
infections.
Our study has some limitations. First, our findings 
focus on early pre-symptomatic infection and might not 
be generalisable to moderate or severe COVID-19 disease. 
Further cohort studies are required to evaluate the 
diagnostic accuracy of IFN-stimulated host transcriptomic 
biomarkers for SARS-CoV-2 infection, particularly in 
the context of more severe disease that could include 
individuals with attenuated IFN responses—perhaps as a 
result of host genetics or anti-cytokine antibodies42–44—
and other immunocompromised groups. Second, we did 
not aim to evaluate discrimination between SARS-CoV-2 
and other acute viral infections, and no PCR testing for 
non-SARS-CoV-2 viruses was done during our study. 
Because of their discovery in various different viral 
infections, we expect these 20 signatures to be non-
specific biomarkers of acute viral infection. The predictive 
value of such biomarkers for SARS-CoV-2 infection will 
be dependent upon pre-test probability, reflecting 
contemporary transmission rates. Nonetheless, their 
sensitivity for detecting pre-symptomatic infection offers 
potential clinical utility for screening contacts of index 
cases of SARS-CoV-2 to inform infection control manage-
ment, and stratify the need for confirmatory viral PCR 
testing. An advantage of non-specific biomarkers of acute 
viral infection is that their application could extend to 
acute respiratory viruses generally, and can potentially be 
multiplexed with prognostic biomarkers. Finally, we 
intentionally focused the aims of the current study on 
validation of pre-existing candidate signatures for viral 
infection for the detection of SARS-CoV-2 to avoid the 
need for splitting of the cohort for discovery and 
validation, with a subsequent loss of statistical power. 
Future studies could consider discovery and validation of 
SARS-CoV-2-specific signatures when sufficient data 
become available.
In summary, our findings suggest that a single transcript 
(IFI27) discriminates between individuals with mild early 
SARS-CoV-2 infection and uninfected healthy individuals 
with high accuracy. If translated to a near-patient 
diagnostic test,46,47 this transcript could have substantial 
clinical utility by facilitating early case detection.
Contributors
CM, TAT, JCM, and MN designed the study. JR, AC, MW, GJ, JA, JL, 
TC-M, CM, TAT, MW, JA, GJ, and HK acquired the data. RKG, JR, LCB, 
JAG-A, GP, and MN analysed the data. RKG, LCB, and MN designed 
and did the systematic literature search. RKG, JR, LCB, DMA, RJB, 
MKM, AM, BMC, CM, TAT, JCM, and MN interpreted the data. 
RKG, JR, LCB, and MN wrote the manuscript with input from all of the 
authors. RKG, JR, and MN accessed and verified the underlying data. 
All authors had full access to all of the data in the study and had final 
responsibility for the decision to submit for publication.
Declaration of interests
We declare no competing interests.
Data sharing
Applications for access to de-identified data for individual participants 
(including data dictionaries) and samples can be made to the access 
committee via an online application. Each application will be reviewed, 
with decisions to approve or reject an application for access made on the 
basis of accordance with participant consent and alignment to the study 
objectives; evidence for the capability of the applicant to undertake the 
specified research; and availability of the requested samples. The use of 
all samples and data will be restricted to the approved application for 
access and stipulated in the material and data transfer agreements 
between participating sites and investigators requesting access. 
Open access to RNAseq data and associated essential metadata are 
available under accession number E-MTAB-10022 at ArrayExpress.
Acknowledgments
Funding for COVIDsortium was donated by individuals, charitable 
trusts, and corporations, including Goldman Sachs, Citadel and Citadel 
Securities, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, 
and Jagclif Charitable Trust, and was enabled by Barts Charity with 
support from University College London Hospitals (UCLH) Charity. 
RKG is funded by the National Institute for Health Research (NIHR; 
DRF-2018-11-ST2-004). JCM, CM, and TAT are directly and indirectly 
supported by the UCLH and Barts NIHR Biomedical Research Centres, 
and through the British Heart Foundation Accelerator Award 
(AA/18/6/34223). TAT is funded by a British Heart Foundation 
Intermediate Research Fellowship (FS/19/35/34374). MN is supported by 
the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research 
Funding to UCL and UCLH. RJB and DMA are supported by grants from 
UK Research and Innovation–Medical Research Council Newton 
(MR/S019553/1, MR/R02622X/1, MR/V036939/1MR/S019553/1, and 
MR/R02622X/1), NIHR Imperial Biomedical Research Centre, the 
Institute for Translational Medicine and Therapeutics, Cystic Fibrosis Trust 
Strategic Research Centre, and Horizon 2020 Marie Curie Actions. 
MKM is supported by the UK Research and Innovation–NIHR UK-COVID 
Immunology Consortium grant, a Wellcome Trust Investigator Award 
(214191/Z/18/Z), and a Cancer Research UK Immunology grant (26603). 
AM is supported by Rosetrees Trust, The John Black Charitable 
Foundation, and Medical College of St Bartholomew’s Hospital Trust.
For the online application for 
data access see https://covid-
consortium.com/application-for-
samples/
For ArrayExpress see https://
www.ebi.ac.uk/arrayexpress/
Articles
10 www.thelancet.com/microbe   Published online July 6, 2021   https://doi.org/10.1016/S2666-5247(21)00146-4
References
1 Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. 
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, 
duration of viral shedding, and infectiousness: a systematic review 
and meta-analysis. Lancet Microbe 2020; 2: e13–22.
2 Kasper MR, Geibe JR, Sears CL, et al. An outbreak of COVID-19 on 
an aircraft carrier. N Engl J Med 2020; 383: 2417–26.
3 Sayampanathan AA, Heng CS, Pin PH, Pang J, Leong TY, Lee VJ. 
Infectivity of asymptomatic versus symptomatic COVID-19. Lancet 
2020; 397: 93–94.
4 Burki T. Mass testing for COVID-19. Lancet Microbe 2020; 1: e317.
5 Dobrow MJ, Hagens V, Chafe R, Sullivan T, Rabeneck L. 
Consolidated principles for screening based on a systematic review 
and consensus process. CMAJ 2018; 190: e422.
6 Deeks JJ, Raffle AE. Lateral flow tests cannot rule out SARS-CoV-2 
infection. BMJ 2020; 371: m4787.
7 Younes N, Al-Sadeq DW, AL-Jighefee H, et al. Challenges in 
laboratory diagnosis of the novel coronavirus SARS-CoV-2. Viruses 
2020; 12: 582.
8 Mustafa Hellou M, Górska A, Mazzaferri F, et al. Nucleic acid 
amplification tests on respiratory samples for the diagnosis of 
coronavirus infections: a systematic review and meta-analysis. 
Clin Microbiol Infect 2021; 27: 341–51.
9 Watson J, Whiting PF, Brush JE. Interpreting a COVID-19 test 
result. BMJ 2020; 369: m1808.
10 Herberg JA, Kaforou M, Wright VJ, et al. Diagnostic test accuracy of 
a 2-transcript host RNA signature for discriminating bacterial vs 
viral infection in febrile children. JAMA 2016; 316: 835–45.
11 Lydon EC, Henao R, Burke TW, et al. Validation of a host response 
test to distinguish bacterial and viral respiratory infection. 
EBioMedicine 2019; 48: 453–61.
12 Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial 
and viral infections via integrated host gene expression diagnostics. 
Sci Transl Med 2016; 8: 346ra91.
13 Sampson D, Yager TD, Fox B, et al. Blood transcriptomic 
discrimination of bacterial and viral infections in the emergency 
department: a multi-cohort observational validation study. 
BMC Med 2020; 18: 185.
14 Gómez-Carballa A, Cebey-López M, Pardo-Seco J, et al. A qPCR 
expression assay of IFI44L gene differentiates viral from bacterial 
infections in febrile children. Sci Rep 2019; 9: 1–12.
15 Lopez R, Wang R, Seelig G. A molecular multi-gene classifier for 
disease diagnostics. Nature Chem 2018; 10: 746–54.
16 Sampson DL, Fox BA, Yager TD, et al. A four-biomarker blood 
signature discriminates systemic inflammation due to viral 
infection versus other etiologies. Sci Rep 2017; 7: 1–17.
17 Sweeney TE, Shidham A, Wong HR, Khatri P. A comprehensive 
time-course-based multicohort analysis of sepsis and sterile 
inflammation reveals a robust diagnostic gene set. Sci Transl Med 
2015; 7: 287ra71.
18 Trouillet-Assant S, Viel S, Ouziel A, et al. Type I interferon in 
children with viral or bacterial infections. Clin Chem 2020; 
66: 802–08.
19 Tsalik EL, Henao R, Nichols M, et al. Host gene expression 
classifiers diagnose acute respiratory illness etiology. Sci Transl Med 
2016; 8: 322ra11.
20 Pennisi I, Rodriguez-Manzano J, Moniri A, et al. Translation of a 
host blood RNA signature distinguishing bacterial from viral 
infection into a platform suitable for development as a 
point-of-care test. JAMA Pediatr 2021; 175: 417–19.
21 Zaas AK, Burke T, Chen M, et al. A host-based RT-PCR gene 
expression signature to identify acute respiratory viral infection. 
Sci Transl Med 2013; 5: 203ra126.
22 McClain MT, Constantine FJ, Nicholson BP, et al. A blood-based 
host gene expression assay for early detection of respiratory viral 
infection: an index-cluster prospective cohort study. 
Lancet Infect Dis 2021; 21: 396–404.
23 Andres-Terre M, McGuire HM, Pouliot Y, et al. Integrated, 
multi-cohort analysis identifies conserved transcriptional 
signatures across multiple respiratory viruses. Immunity 2015; 
43: 1199.
24 Henrickson SE, Manne S, Dolfi DV, et al. Genomic circuitry 
underlying immunological response to pediatric acute respiratory 
infection. Cell Rep 2018; 22: 411–26.
25 Brand HK, Ahout IML, Ridder D de, et al. Olfactomedin 4 serves as 
a marker for disease severity in pediatric respiratory syncytial virus 
(RSV) Infection. PLoS One 2015; 10: e0131927.
26 Augusto JB, Menacho K, Andiapen M, et al. Healthcare Workers 
Bioresource: study outline and baseline characteristics of a 
prospective healthcare worker cohort to study immune protection 
and pathogenesis in COVID-19. Wellcome Open Res 2020; 5: 179.
27 Treibel TA, Manisty C, Burton M, et al. COVID-19: PCR screening 
of asymptomatic health-care workers at London hospital. Lancet 
2020; 395: 1608–10.
28 Reynolds CJ, Swadling L, Gibbons JM, et al. Discordant 
neutralizing antibody and T cell responses in asymptomatic and 
mild SARS-CoV-2 infection. Sci Immunol 2020; 5: eabf3698.
29 Gupta RK, Turner CT, Venturini C, et al. Concise whole blood 
transcriptional signatures for incipient tuberculosis: a systematic 
review and patient-level pooled meta-analysis. Lancet Respir Med 
2020; 8: 395–406.
30 Turner CT, Gupta RK, Tsaliki E, et al. Blood transcriptional 
biomarkers for active pulmonary tuberculosis in a high-burden 
setting: a prospective, observational, diagnostic accuracy study. 
Lancet Respir Med 2020; 8: 407–19.
31 Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal 
probabilistic RNA-seq quantification. Nat Biotechnol 2016; 34: 525–27.
32 Soneson C, Love MI, Robinson MD. Differential analyses for 
RNA-seq: transcript-level estimates improve gene-level inferences. 
F1000Res 2016; 4: 1521.
33 Durinck S, Moreau Y, Kasprzyk A, et al. BioMart and Bioconductor: 
a powerful link between biological databases and microarray data 
analysis. Bioinformatics 2005; 21: 3439–40.
34 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas 
under two or more correlated receiver operating characteristic 
curves: a nonparametric approach. Biometrics 1988; 44: 837–45.
35 Zaas AK, Chen M, Varkey J, et al. Gene expression signatures 
diagnose influenza and other symptomatic respiratory viral 
infections in humans. Cell Host Microbe 2009; 6: 207–17.
36 Ramilo O, Allman W, Chung W, et al. Gene expression patterns in 
blood leukocytes discriminate patients with acute infections. Blood 
2007; 109: 2066–77.
37 Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O. 
MxA gene expression after live virus vaccination: a sensitive marker 
for endogenous type I interferon. J Infect Dis 1994; 169: 807–13.
38 Pescarmona R, Belot A, Villard M, et al. Comparison of RT-qPCR and 
Nanostring in the measurement of blood interferon response for the 
diagnosis of type I interferonopathies. Cytokine 2019; 113: 446–52.
39 Yu J, Peterson DR, Baran AM, et al. Host Gene expression in nose 
and blood for the diagnosis of viral respiratory infection. J Infect Dis 
2019; 219: 1151–61.
40 Huang Y, Zaas AK, Rao A, et al. Temporal dynamics of host 
molecular responses differentiate symptomatic and asymptomatic 
influenza a infection. PLoS Genet 2011; 7: e1002234.
41 Tang BM, Shojaei M, Parnell GP, et al. A novel immune biomarker 
IFI27 discriminates between influenza and bacteria in patients with 
suspected respiratory infection. Eur Respir J 2017; 49: 1602098.
42 Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms 
of critical illness in COVID-19. Nature 2021; 591: 92–98.
43 Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN 
immunity in patients with life-threatening COVID-19. Science 2020; 
370: eabd4570.
44 Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I 
IFNs in patients with life-threatening COVID-19. Science 2020; 
370: eabd4585.
45 Rosebeck S, Leaman DW. Mitochondrial localization and 
pro-apoptotic effects of the interferon-inducible protein ISG12a. 
Apoptosis 2008; 13: 562–72.
46 Tsalik EL, Henao R, Aydin M, et al. 2012. FilmArray® 
measurement of host response signatures rapidly discriminates 
viral, bacterial, and non-infectious etiologies of illness. 
Open Forum Infect Dis 2018; 5: S586.
47 Miller III RR, Lopansri BK, Burke JP, et al. Validation of a host 
response assay, SeptiCyte LAB, for discriminating sepsis from 
systemic inflammatory response syndrome in the ICU. 
Am J Respir Crit Care Med 2018; 198: 903–13.
